메뉴 건너뛰기




Volumn 84, Issue 1, 2007, Pages 126-

Is low-dose valganciclovir the same as appropriate-dose valganciclovir? [1]

Author keywords

[No Author keywords available]

Indexed keywords

CREATININE; GANCICLOVIR; VALGANCICLOVIR;

EID: 34447632053     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.tp.0000268508.58468.ff     Document Type: Letter
Times cited : (6)

References (9)
  • 1
    • 33846995945 scopus 로고    scopus 로고
    • Oral ganciclovir versus low-dose valganciclovir for prevention of cytomegalovirus disease in recipients of kidney and pancreas transplants
    • Weng FL, Patel AM, Wanchoo R, et al. Oral ganciclovir versus low-dose valganciclovir for prevention of cytomegalovirus disease in recipients of kidney and pancreas transplants. Transplantation 2007; 83: 290.
    • (2007) Transplantation , vol.83 , pp. 290
    • Weng, F.L.1    Patel, A.M.2    Wanchoo, R.3
  • 2
    • 20144385981 scopus 로고    scopus 로고
    • Cytomegalovirus prophylaxis with valganciclovir in African-American renal allograft recipients based on donor/recipient serostatus
    • Gruber SA, Garnick J, Morawski K, et al. Cytomegalovirus prophylaxis with valganciclovir in African-American renal allograft recipients based on donor/recipient serostatus. Clin Transplant 2005; 19: 273.
    • (2005) Clin Transplant , vol.19 , pp. 273
    • Gruber, S.A.1    Garnick, J.2    Morawski, K.3
  • 3
    • 4644339105 scopus 로고    scopus 로고
    • Efficacy and safety of low-dose valganciclovir for prevention of cytomegalovirus disease in renal transplant recipients: A single-center, retrospective analysis
    • Gabardi S, Magee CC, Baroletti SA, et al. Efficacy and safety of low-dose valganciclovir for prevention of cytomegalovirus disease in renal transplant recipients: A single-center, retrospective analysis. Pharmacotherapy 2004; 24: 1323.
    • (2004) Pharmacotherapy , vol.24 , pp. 1323
    • Gabardi, S.1    Magee, C.C.2    Baroletti, S.A.3
  • 4
    • 0037531594 scopus 로고    scopus 로고
    • Cytomegalovirus disease in high-risk transplant recipients despite ganciclovir or valganciclovir prophylaxis
    • Akalin E, Sehgal V, Ames S, et al. Cytomegalovirus disease in high-risk transplant recipients despite ganciclovir or valganciclovir prophylaxis. Am J Transplant 2003; 3: 731.
    • (2003) Am J Transplant , vol.3 , pp. 731
    • Akalin, E.1    Sehgal, V.2    Ames, S.3
  • 5
    • 18644362332 scopus 로고    scopus 로고
    • Cytomegalovirus prophylaxis using oral ganciclovir or valganciclovir in kidney and pancreas-kidney transplantation under antibody preconditioning
    • Keven K, Basu A, Tan HP, et al. Cytomegalovirus prophylaxis using oral ganciclovir or valganciclovir in kidney and pancreas-kidney transplantation under antibody preconditioning. Transplant Proc 2004; 36: 3107.
    • (2004) Transplant Proc , vol.36 , pp. 3107
    • Keven, K.1    Basu, A.2    Tan, H.P.3
  • 6
    • 1942469969 scopus 로고    scopus 로고
    • Efficacy and safety of valganciclovir vs. oral ganciclovir for prevention of cytomegalovirus disease in solid organ transplant recipients
    • Paya C, Humar A, Dominguez E, et al. Efficacy and safety of valganciclovir vs. oral ganciclovir for prevention of cytomegalovirus disease in solid organ transplant recipients. Am J Transplant 2004; 4: 611.
    • (2004) Am J Transplant , vol.4 , pp. 611
    • Paya, C.1    Humar, A.2    Dominguez, E.3
  • 7
    • 0033807143 scopus 로고    scopus 로고
    • Valganciclovir results in improved oral absorption of ganciclovir in liver transplant recipients
    • Pescovitz MD, Rabkin J, Merion RM, et al. Valganciclovir results in improved oral absorption of ganciclovir in liver transplant recipients. Antimicrobial Agents Chemother 2000; 44: 2811.
    • (2000) Antimicrobial Agents Chemother , vol.44 , pp. 2811
    • Pescovitz, M.D.1    Rabkin, J.2    Merion, R.M.3
  • 8
    • 21144452373 scopus 로고    scopus 로고
    • Pharmacokinetic profile of ganciclovir after its oral administration and from its prodrug, valganciclovir, in solid organ transplant recipients
    • Wiltshire H, Hirankarn S, Farrell C, et al. Pharmacokinetic profile of ganciclovir after its oral administration and from its prodrug, valganciclovir, in solid organ transplant recipients. Clin Pharmacokinet 2005; 44: 495.
    • (2005) Clin Pharmacokinet , vol.44 , pp. 495
    • Wiltshire, H.1    Hirankarn, S.2    Farrell, C.3
  • 9
    • 0031581506 scopus 로고    scopus 로고
    • Randomised trial of efficacy and safety of oral ganciclovir in the prevention of cytomegalovirus disease in liver-transplant recipients
    • Letters to the Editor
    • Gane E, Saliba F, Valdecasas GJ, et al. Randomised trial of efficacy and safety of oral ganciclovir in the prevention of cytomegalovirus disease in liver-transplant recipients. Lancet 1997; 350: 1729. Letters to the Editor
    • (1997) Lancet , vol.350 , pp. 1729
    • Gane, E.1    Saliba, F.2    Valdecasas, G.J.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.